10 Mar, 2017 09:13 AM
In addition to the Melbourne and Sydney mid-year shareholder briefings, Noxopharm Limited now invites shareholders and interested parties to attend a Company briefing on:
The Company’s forma...read more
01 Feb, 2017 08:15 AM
Sydney, 1 February: Noxopharm announces that it has entered into a research agreement with the University of Hong Kong to conduct research into the use of the drug idronoxil (NOX66 active ingredient) ...read more
31 Jan, 2017 09:29 AM
Sydney, 31 January: Noxopharm Limited announces that its first NOX66 Phase 1a/1b clinical study involving NOX66 has received approval from the Georgian Ministry of Health to begin recruitment.
This...read more
22 Nov, 2016 02:17 PM
Our objective
To bring to market the first drug that sensitises cancer cells to cancer therapies, to improve the survival outcomes of standard chemotherapy and radiotherapy, and allow effective dos...read more
26 Oct, 2016 10:17 AM
Noxopharm Limited (ASX:NOX) confirms that its inaugural clinical study of
experimental anti-cancer product, NOX66, is on schedule to open in December
2016.
The Phase 1a/1b study is being conducte...read more
25 Oct, 2016 09:05 PM
Following the Company’s AGM in Melbourne on November 23, 2016, Noxopharm Limited ( ASX: NOX) will be holding an AGM Sydney Briefing on November 25th at 4pm at the Grace Hotel, 77 York Street, Sy...read more
21 Oct, 2016 08:46 AM
In a nutshell….
In 1971, cancer researchers dreamt of turning cancer into a manageable, non-lethal, chronic disease
45 years later that dream remains elusive for most types of cancer
I...read more
